Your account is not claimed yet. You can sign up with ORCID to claim your account.

Jian Li

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 41

Top Venues

Peking Union Medical College Hospital

Chinese Academy of Medical Sciences and Peking Union Medical College (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Peking Union Medical College Hospital Sep 1o 2017

China

Professor :: Hematology

Education History

Chinese Academy of Medical Sciences and Peking Union Medical College Sep 1o 1993 - Jul 1o 2001

China

PHD :: Medicine

Publications

Miao-Yan Zhang, Jian Li, Yi-Ning Wang, Zhuang Tian, Lu Zhang
Unicentric Castleman's disease presenting as amyloid A cardiac amyloidosis: a case report. Annals of hematology (2023)
Yuan Jian, Long Chang, Ming-Xia Shi, Ying Sun, Xiao-Xia Chu, Hua Xue, Wen-Rong Huang, Xu-Liang Shen, Jie Ma, Guo-Rong Jia, Ya-Qing Feng, Zhen-Fang Xi, Yan-Hong Zhao, Yan-Ping Ma, Jing Xiao, Guang-Yu Ma, Qing-Ming Wang, Li Bao, Yu-Jun Dong, He-Bing Zhou, Chunyan Sun, Guo-Hong Su, Yan Yan, Sai-Yin Qimuge, Li-Ping Su, Jing-Nan Sun, Wei-Wei Tian, Xiu-Li Sun, Hong-Mei Jing, Da Gao, Wen-Ming Chen, Jian Li, Wen Gao
Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment. Blood advances (2023)
Ji-Nuo Wang, Ting Liu, Ai-Lin Zhao, Bo-Ju Pan, Jian Sun, Jian Li, Dao-Bin Zhou, Xin-Xin Cao, Ming-Hui Duan
Correction: Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis. Leukemia (2023)
ShuQing Wang, Xuan Wang, KaiNi Shen, Chong Wei, Jian Li
Insulin-like growth factor 1 receptor inhibits the proliferation of acute myeloid leukaemia cells via NK cell activation. Annals of hematology (2023)
Hong-Xiao Han, Long Chang, Min Lang, He Lin, Jian Li, Ming-Hui Duan, Dao-Bin Zhou, Xin-Xin Cao
Clinical characteristics, genomic profiling and outcomes of single system multifocal Langerhans cell histiocytosis in adults with bone involvement. Blood cancer journal 13 (1) (2023)
An-An Li, Yan-Ying Yu, Xue-Min Gao, Hao Zhao, Xin-Xin Cao, Lu Zhang, Dao-Bin Zhou, Jian Li
Treatment and outcome of second-line therapy for POEMS syndrome after autologous stem cell transplantation. Bone marrow transplantation (2023)
Kai-Ni Shen, Dan-Qing Zhao, Yue-Ying Mao, Hua-Cong Cai, Jian Li, Xin-Xin Cao
Daratumumab-based regimen for cold agglutinin disease refractory to therapy directing B-cell clone. Leukemia & lymphoma (2023)
Long Chang, Bing Qiao, Hao Cai, He Lin, Ming-Hui Duan, Jian Li, Dao-Bin Zhou, Gaurav Goyal, Chun-Yan Sun, Xin-Xin Cao
Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease. Leukemia (2023)
Chunmei Kuang, Meijuan Xia, Gang An, CuiCui Liu, Cong Hu, Jingyu Zhang, Zhenhao Liu, Bin Meng, Pei Su, Jiliang Xia, Jiaojiao Guo, Yinghong Zhu, Xing Liu, Xuan Wu, Yi Shen, Xiangling Feng, Yanjuan He, Jian Li, Lugui Qiu, Jiaxi Zhou, Wen Zhou
Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma. Nature communications 14 (1) (2023)
Hao Zhao, Miao-Yan Zhang, Kai-Ni Shen, Jun Feng, Xin-Xin Cao, Ming-Hui Duan, Dao-Bin Zhou, Lu Zhang, Jian Li
A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in newly-diagnosed iMCD patients. Blood (2023)
Ya-Juan Gao, Kai-Ni Shen, Hui-Lei Miao, Zhuang Tian, Jun Feng, Lu Zhang, Xin-Xin Cao, Dao-Bin Zhou, Jian Li
A retrospective study of ultrahigh-risk (Mayo 2004 stage IIIb) AL amyloidosis and identification of predictors related to extremely early death. Leukemia & lymphoma 63 (7) (2022)
Ai-Lin Zhao, Hao Cai, Jia Chen, Ming-Hui Duan, Dao-Bin Zhou, Jian Li, Xin-Xin Cao
The potential of cell-free DNA to reveal the molecular profiles of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Leukemia 36 (5) (2022)
Yujie Shi, Jian Li, Lu Zhang
Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report. Annals of hematology 101 (11) (2022)
Ji-Nuo Wang, Ting Liu, Ai-Lin Zhao, Bo-Ju Pan, Jian Sun, Jian Li, Dao-Bin Zhou, Xin-Xin Cao, Ming-Hui Duan
Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis. Leukemia 36 (6) (2022)
Lu Zhang, Miao-Yan Zhang, Xin-Xin Cao, Dao-Bin Zhou, David C Fajgenbaum, Yu-Jun Dong, Jian Li
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD. Leukemia & lymphoma 63 (3) (2022)
Chunyan Sun, Jian Xu, Bo Zhang, Haifan Huang, Lei Chen, Han Yan, Aoshuang Xu, Fei Zhao, Daijuan Huang, Liqiong Liu, Jian Li, Yu Hu
Whole-genome sequencing suggests a role of MIF in the pathophysiology of TEMPI syndrome. Blood advances 5 (12) (2021)
Yan-Ying Yu, Xue-Min Gao, Hao Zhao, Hao Cai, Jun Feng, Lu Zhang, Xin-Xin Cao, Daobin Zhou, Jian Li
Treatment and outcomes of POEMS syndrome: changes in the past 20 years. Blood cancer journal 11 (8) (2021)
Xue-Min Gao, Yan-Ying Yu, Hao Zhao, Hao Cai, Lu Zhang, Xin-Xin Cao, Dao-Bin Zhou, Jian Li
Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome. Annals of hematology 100 (11) (2021)
Jia Chen, Ai-Lin Zhao, Ming-Hui Duan, Hao Cai, Xue-Min Gao, Ting Liu, Jian Sun, Zhi-Yong Liang, Dao-Bin Zhou, Xin-Xin Cao, Jian Li
Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis. Leukemia (2021)
Xin-Xin Cao, Shu-Hua Yi, Zhong-Xing Jiang, Jing-Song He, Wei Yang, Juan Du, Chun-Yan Sun, Yu Wu, Wen-Ming Chen, Xiao-Jun Liu, Bing-Zong Li, Chun-Rui Li, Wei Sang, Qin-Hua Liu, Xiao-Xia Chu, Fei Li, Ou Bai, Min Mao, Rong Fu, Wei Wang, Li-Hong Liu, Lu-Qun Wang, Yu-Jun Dong, Jun Luo, Zhen-Ling Li, Yong-Qiang Wei, Qi-Ke Zhang, Jing Liu, Kai-Yang Ding, Liang Zou, Bi-Yun Chen, Luo-Ming Hua, Hong-Mei Jing, Juan He, Liang Wang, Jian Li, Lu-Gui Qiu
Treatment and outcome patterns of patients with Waldenström's macroglobulinemia: a large, multicenter retrospective review in China. Leukemia & lymphoma 62 (11) (2021)
Kai-Ni Shen, Hui-Lei Miao, Lu Zhang, Jun Feng, Xin-Xin Cao, Jian Li
Validation of the composite organ and hematologic response model for prognostic prediction in a Chinese light chain amyloidosis cohort. Leukemia & lymphoma 62 (8) (2021)
Xin-Xin Cao, Ming-Hui Duan, Ai-Lin Zhao, Hao Cai, Jia Chen, Xue-Min Gao, Ting Liu, Hua-Cong Cai, Lu Zhang, Jian Sun, Zhi-Yong Liang, Dao-Bin Zhou, Jian Li
Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis. American journal of hematology (2021)
Jian Li
Reply to "POEMS syndrome remains a mystery after 40 years" (Wang Chen. 20-LEU-1856). Leukemia 35 (4) (2021)
Qian-Qian Cai, Xue-Min Gao, Jing Le, Hao Zhao, Hao Cai, Xin-Xin Cao, Jian Li
Cereblon expression is a prognostic marker in newly diagnosed POEMS syndrome treated with lenalidomide plus dexamethasone. Annals of hematology 100 (6) (2021)
Kai-Ni Shen, Wei-Jun Fu, Yu Wu, Yu-Jun Dong, Zhong-Xia Huang, Yong-Qiang Wei, Chun-Rui Li, Chun-Yan Sun, Ye Chen, Hui-Lei Miao, Yue-Lun Zhang, Xin-Xin Cao, Dao-Bin Zhou, Jian Li
Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial. Circulation (2021)
Jia Chen, Xue-Min Gao, Hao Zhao, Hao Cai, Lu Zhang, Xin-Xin Cao, Dao-Bin Zhou, Jian Li
A highly heterogeneous mutational pattern in POEMS syndrome. Leukemia 35 (4) (2020)
Kai-Ni Shen, Hui-Lei Miao, Cong-Li Zhang, Jun Feng, Lu Zhang, Xin-Xin Cao, Dao-Bin Zhou, Su Wei, Jian Li
Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib. Leukemia & lymphoma 62 (4) (2020)
Yan-Yan Wu, Ming-Nan Jia, Hao Cai, Yu Qiu, Dao-Bin Zhou, Jian Li, Xin-Xin Cao
Detection of the MYD88L265P and CXCR4S338X mutations by cell-free DNA in Waldenström macroglobulinemia. Annals of hematology 99 (8) (2020)
Lu Zhang, Qin Wang, Xia Wu, Ailin Zhao, Jun Feng, Haibo Zhang, Xinxin Cao, Shuo Li, Huacong Cai, Zhaoyong Sun, Minghui Duan, Tienan Zhu, Wei Zhang, Zhengyu Jin, Daobin Zhou, Huadan Xue, Jian Li
Baseline bone marrow ADC value of diffusion-weighted MRI: a potential independent predictor for progression and death in patients with newly diagnosed multiple myeloma. European radiology 31 (4) (2020)
Hui-Lei Miao, Ai-Lin Zhao, Ming-Hui Duan, Dao-Bin Zhou, Xin-Xin Cao, Jian Li
Clinical presentation and prognostic analysis of adult patients with Langerhans cell histiocytosis with pulmonary involvement. BMC cancer 20 (1) (2020)
Le-le Zhang, Xin-Xin Cao, Kai-Ni Shen, Hong-Xiao Han, Cong-Li Zhang, Yu Qiu, Hao Zhao, Xue-Min Gao, Jun Feng, Lu Zhang, Dao-Bin Zhou, Jian Li
Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients. Annals of hematology 99 (8) (2020)
Jian-Hua Han, Ji-Nuo Wang, Yue-Lun Zhang, Xin-Xin Cao, Dao-Bin Zhou, Teng-da Xu, Wei Su, Jian Li
Prevalence of monoclonal gammopathy of undetermined significance in a large population with annual medical check-ups in China. Blood cancer journal 10 (3) (2020)
Hao Zhao, Xu-Fei Huang, Xue-Min Gao, Hao Cai, Lu Zhang, Jun Feng, Xin-Xin Cao, Dao-Bin Zhou, Jian Li
What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone? Leukemia 33 (4) (2019)
Tianhua He, Ailin Zhao, Hao Zhao, Hao Cai, Jun Feng, Lu Zhang, Xinxin Cao, Daobin Zhou, Jian Li
Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy. Annals of hematology 98 (3) (2019)
Xia Wu, Hui-Lei Miao, Tie-Nan Zhu, Jun Feng, Lu Zhang, Yue-Ying Mao, Dao-Bin Zhou, Xin-Xin Cao, Jian Li
Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 26 (4) (2019)
Ji-Nuo Wang, Yu Qiu, Na Niu, Yan Zhang, Jian Li, Dao-Bin Zhou, Xin-Xin Cao
Successful treatment of central nervous system involved Erdheim-Chester disease by intermediate-dose cytarabine as first-line therapy. Acta oncologica (Stockholm, Sweden) 59 (3) (2019)
Lu Zhang, Ai-Lin Zhao, Ming-Hui Duan, Zhi-Yuan Li, Xin-Xin Cao, Jun Feng, Dao-Bin Zhou, Ding-Rong Zhong, David C Fajgenbaum, Jian Li
Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood 133 (16) (2019)
Xu-Fei Huang, Sun Jian, Jun-Liang Lu, Kai-Ni Shen, Jun Feng, Cong-Li Zhang, Zhuang Tian, Jia-Li Wang, Wan-Jun Lei, Xin-Xin Cao, Dao-Bin Zhou, Zhi-Yong Liang, Jian Li
Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 27 (1) (2019)
Yujun Dong, Lu Zhang, Lin Nong, Lihong Wang, Zeyin Liang, Daobin Zhou, David C Fajgenbaum, Hanyun Ren, Jian Li
Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. Annals of hematology 97 (9) (2018)
Yu Qiu, Cong-Li Zhang, Kai-Ni Shen, Wei Su, Jun Feng, Lu Zhang, Xin-Xin Cao, Jian Li
Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels. Annals of hematology 97 (12) (2018)
Xin-Xin Cao, Na Niu, Jian Sun, Dao-Bin Zhou, Jian Li
Efficacy of intermediate-dose cytarabine in central nervous system-relapsed wild-type BRAF Erdheim-Chester disease. Annals of hematology 97 (1) (2017)

Jian Li.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jian Li